Crain’s Detroit Business Profiles ALS Trial
"I know what a placebo effect is. I'm not crazy. This isn't a placebo effect," Ted Harada told one of his doctors last year, practically yelling it at him in a burst of enthusiasm.
Harada, 40, a former manager at FedEx Corp., was one of 15 ALS patients who were part of a recently completed U.S. Food and Drug Administration Phase 1 trial at Emory University in Atlanta -- a trial designed and run in part by researchers at the University of Michigan to inject stem cells into the spine of patients with amyotrophic lateral sclerosis.
Full article - ALS patient: 'This isn't a placebo effect' (PDF)
Stem cell research nears next phase; trials may come to Ann Arbor
Approval by the U.S. Food and Drug Administration is expected any day for researchers and physicians at the University of Michigan to begin a second round of Phase 1 stem cell trials on patients with amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease.
ALS is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement. It usually leads to death within three to five years. Currently, there is no cure.
Full article - Advancing on ALS (PDF)
Dr. Eva Feldman: Alfred Taubman as mentor, leader, friend
The source of his greatness lay in his willingness to challenge conventional thinking.
Emerging Scholars publish new findings on basal cell cancer
Ophthalmologists Alon Kahana, MD, PhD and Rajesh Rao, MD are trying to pinpoint when the common cancer turns dangerous.
Dr. Max Wicha receives $6.5 million to target cancer stem cells
The award from the National Cancer Institute will fuel research into the cells that cause metastasis.
news & events
In the News
Taubman Emerging Scholar partners in ACL repair study
Asheesh Bedi, M.D., is an investigator in a study using human growth hormone to aid healing of the common knee injury.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D. and team find a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Arthritis drug may help diabetics with kidney disease
Research led by Taubman Scholar Frank Brosius has led to a fast-track study that shows promising results